Showing 6551-6560 of 9807 results for "".
- Common Soap Ingredient May Alter Skin's Wettabilityhttps://practicaldermatology.com/news/common-soap-ingredient-may-alter-skins-wettability/2458139/New research suggests that it is possible to alter the wettability of your skin using an ingredient commonly found in cosmetic cleaners. In a recent study, Guy German, PhD, an assistant professor of biomedical engineering at Binghamton University, State University of New York, along with
- No Need to Delay Certain Skin Procedures for Isotretinoin Patientshttps://practicaldermatology.com/news/no-need-to-delay-certain-skin-procedures-for-isotretinoin-patients/2458140/New consensus recommendations set the record straight on the timing of skin procedures for patients taking isotretinoin. After reviewing 32 relevant publications, the authors found “insufficient evidence” to support delaying manual dermabrasion, superficial chemical peels
- Sciton Rewards Consumer in New Sweepstakeshttps://practicaldermatology.com/news/sciton-rewards-consumer-in-new-sweepstakes/2458143/Consumers can win $1,000 towards one of several Sciton treatments including Halo, BBL, Contour TRL, and diVa Laser Vaginal Therapy as part of an ongoing national sweepstakes. The Sciton consumer sweepstakes runs through August 23, with one w
- ASDS: Percentage of Us Wanting Cosmetic Surgery Doubled Since 2013https://practicaldermatology.com/news/asds-percentage-of-us-wanting-cosmetic-surgery-doubled-since-2013/2458141/Nearly 70 percent of consumers now say they are thinking about getting a cosmetic treatment, according to survey data released by the American Society for Dermatologic Surgery (ASDS). The ASDS Consumer
- FDA Approves New Antibiotic for Skin Infectionshttps://practicaldermatology.com/news/fda-approves-new-antibiotic-for-skin-infections/2458149/The FDA has approved Melinta Therapeutics' Baxdela (delafloxacin) for adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathog
- Study Findings Cast Doubt on Link Between Eczema and Cardiovascular Diseasehttps://practicaldermatology.com/news/study-findings-cast-doubt-on-link-between-eczema-and-cardiovascular-disease/2458151/Despite recent findings to the contrary, a new study in the British Journal of Dermatology has found that eczema is likely not associated with an increase in cardiovascular risk factors or diseases. "In our study, people who reported having atopic dermatitis were not at any
- Coppertone Whips Up Excitement About New Sunscreen Linehttps://practicaldermatology.com/news/coppertone-whips-up-excitement-about-new-sunscreen-line/2458152/Coppertone is going all out to launch their new Whipped line, available in both CLEARLYSheer® and WaterBABIES® Pure & Simple formulas, including partnering with beauty influencers and the Skin Cancer Foundation. The brand is promot
- FDA Cracks Down on Sonar For Distributing Unapproved Derm Drugshttps://practicaldermatology.com/news/fda-cracks-down-on-sonar-for-distributing-unapproved-derm-drugs/2458153/U.S. District Judge Kathleen M. Williams for the Southern District of Florida entered a consent decree of permanent injunction between the United States and Stratus Pharmaceuticals Inc. of Miami, Florida, Sonar Products Inc. of Carlstadt, New Jersey an
- Some Hair Products May Up Breast Cancer Risk in Certain Womenhttps://practicaldermatology.com/news/some-hair-products-may-up-breast-cancer-risk-in-some-women/2458156/Use of hair dyes may increase risk for breast cancer among certain women, new research suggests. Specifically, dark brown or black hair dye was associated with a 51 percent increased overall risk of developing breast cancer among African American women, and a 72 percent increased risk of
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients